Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company, valued at $1,184,491.04. This trade represents a 54.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Performance

NASDAQ IMNM opened at $21.84 on Friday. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $27.65. The stock has a market cap of $2.47 billion, a PE ratio of -9.02 and a beta of 2.13. The stock’s 50 day moving average is $22.34 and its 200 day moving average is $19.29.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently made changes to their positions in the business. Stoneridge Investment Partners LLC raised its position in shares of Immunome by 5.4% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock valued at $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its position in Immunome by 6.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after acquiring an additional 631 shares in the last quarter. Creative Planning grew its position in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after acquiring an additional 935 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Immunome by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after acquiring an additional 1,167 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on IMNM shares. Evercore boosted their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Guggenheim raised their price objective on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Stephens reduced their target price on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Leerink Partners set a $40.00 price target on Immunome in a research note on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.